FUSN - Fusion Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
15.89
-0.53 (-3.23%)
As of 3:36PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close16.42
Open16.55
Bid15.85 x 1000
Ask15.89 x 1200
Day's Range15.86 - 16.93
52 Week Range15.00 - 19.00
Volume174,909
Avg. Volume860,725
Market Cap662.041M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount
      CNW Group

      H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount

      H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount

    • Barrons.com

      e.l.f. Beauty, Akouos See Activist Actions

      Marathon Partners disclosed a large stake in cosmetics retailer e.l.f. Beauty. New Enterprise Associates now has a large stake in the newly public shares of gene-therapies firm Akouos.

    • Fusion Pharmaceuticals Announces Pricing of Initial Public Offering
      PR Newswire

      Fusion Pharmaceuticals Announces Pricing of Initial Public Offering

      Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17.00 per share. All of the shares are being offered by Fusion. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Fusion, are expected to be $212.5 million. In addition, Fusion has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 common shares at the initial public offering price.